Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts)

被引：6
作者：
Gupta, S. [1 ]
Climent Duran, M. A. [2 ]
Sridhar, S. [3 ]
Powles, T. B. [4 ]
Bellmunt, J. [5 ]
Tyroller, K. [6 ]
Guenther, S. [7 ]
di Pietro, A. [8 ]
Grivas, P. [9 ]
机构：
[1] Cleveland Clin Fdn, Taussig Canc Inst, Cleveland, OH USA
[2] Inst Valenciano Oncol, Valencia, Spain
[3] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Queen Mary Univ London, Barts Canc Inst, Expt Canc Med Ctr, St Bartholomews Hosp, London, England
[5] Dana Farber Canc Inst, Harvard Med Sch, Dept Med Oncol, Boston, MA USA
[6] EMD Serono Res & Dev Inst Inc, Billerica, MA USA
[7] Merck Healthcare KGaA, Darmstadt, Germany
[8] Pfizer Srl, Milan, Italy
[9] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1020
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2371P
引用
收藏
页码：S1207 / S1207
页数：1
相关论文
共 50 条
[41]   Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial [J].
Thomas Powles ;
Srikala S. Sridhar ;
Yohann Loriot ;
Joaquim Bellmunt ;
Xinmeng Jasmine Mu ;
Keith A. Ching ;
Jie Pu ;
Cora N. Sternberg ;
Daniel P. Petrylak ;
Rosa Tambaro ;
Louis M. Dourthe ;
Carlos Alvarez-Fernandez ;
Maureen Aarts ;
Alessandra di Pietro ;
Petros Grivas ;
Craig B. Davis .
Nature Medicine, 2021, 27 :2200-2211
[42]   AVELUMAB FIRST-LINE MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA IN THE JAVELIN BLADDER 100 TRIAL: SUBGROUP ANALYSIS BY DURATION OF TREATMENT-FREE INTERVAL FROM END OF CHEMOTHERAPY TO START OF MAINTENANCE [J].
Sridhar, Srikala S. ;
Powles, Thomas ;
Loriot, Yohann ;
Climent, Miguel A. ;
Gupta, Shilpa ;
Tsuchiya, Norihiko ;
Bamias, Aristotelis ;
Ardizzoni, Andrea ;
Ullen, Anders ;
Huang, Bo ;
Costa, Nuno ;
Laliberte, Robert J. ;
di Pietro, Alessandra ;
Sternberg, Cora N. ;
Grivas, Petros .
JOURNAL OF UROLOGY, 2021, 206 :E997-E997
[43]   Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 Japanese subgroup analysis. [J].
Tsuchiya, Norihiko ;
Yamamoto, Yoshiaki ;
Uemura, Hirotsugu ;
Kanayama, Hiro-Omi ;
Eto, Masatoshi ;
Miyake, Hideaki ;
Powles, Thomas ;
Yoshida, Mizuki ;
Koide, Yuichiro ;
Umeyama, Yoshiko ;
Di Pietro, Alessandra ;
Tomita, Yoshikiko .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[44]   NECTIN4 RNA expression and clinical outcomes with first-line (1L) platinum-based chemotherapy (PBC) and avelumab 1L maintenance in locally advanced or metastatic urothelial carcinoma (la/mUC): Exploratory analyses from JAVELIN Bladder 100. [J].
Kluemper, Niklas ;
Markus, Eckstein ;
Grivas, Petros ;
Grande, Enrique ;
Braegelmann, Johannes ;
Hoffman, Jason ;
Shah, Parantu K. ;
Bogatyrova, Olga ;
Gruenwald, Viktor .
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
[45]   JAVELIN BLADDER MEDLEY: A PHASE 2 TRIAL OF AVELUMAB IN COMBINATION WITH OTHER ANTITUMOR DRUGS AS FIRST-LINE MAINTENANCE THERAPY FOR ADVANCED UROTHELIAL CARCINOMA [J].
Hoffman-Censits, Jean ;
Grivas, Petros ;
Powles, Thomas ;
Martincic, Danko ;
Hawley, Jessica ;
Tyroller, Karin ;
Seeberger, Sonja ;
Guenther, Silke ;
Jacob, Natalia ;
Mehr, Keyvan Tadjalli ;
Hahn, Noah .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 :A695-A695
[46]   Avelumab first-line maintenance in advanced urothelial carcinoma: Complete screening for prognostic and predictive factors using machine learning in the JAVELIN Bladder 100 phase 3 trial [J].
Manitz, Juliane ;
Gerhold-Ay, Aslihan ;
Kieslich, Pascal ;
Shah, Parantu ;
Mrowiec, Thomas ;
Tyroller, Karin .
CANCER MEDICINE, 2024, 13 (12)
[47]   Prognostic impact of first-line (1L) chemotherapy cycles in patients with metastatic urothelial carcinoma receiving avelumab 1L maintenance. [J].
Katayama, Satoshi ;
Kawada, Tatsuhi ;
Kobayashi, Keita ;
Watanabe, Ryuta ;
Tohi, Yoichiro ;
Yamamoto, Shinkuro ;
Takamoto, Atsushi ;
Shimizu, Ryutaro ;
Daizumoto, Kei ;
Nagami, Taichi ;
Wada, Koichiro ;
Miura, Noriyoshi ;
Morizane, Shuichi ;
Furukawa, Junya ;
Inoue, Keiji ;
Sugimoto, Mikio ;
Shiraishi, Koji ;
Araki, Motoo .
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
[48]   First-line maintenance immunotherapy in advanced urothelial cancers: Practice changing implications of the JAVELIN bladder 100 trial [J].
Kumaraswamy, Santosh .
INDIAN JOURNAL OF UROLOGY, 2021, 37 (03) :295-296
[49]   Re: Avelumab Maintenance in Advanced Urothelial Carcinoma: Biomarker Analysis of the Phase 3 JAVELIN Bladder 100 Trial [J].
Chang, Sam S. .
JOURNAL OF UROLOGY, 2023, 209 (03) :634-634
[50]   Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy. [J].
Loriot, Yohann ;
Powles, Thomas ;
Duran, Climent Miguel Angel ;
Sridhar, Srikala S. ;
Bellmunt, Joaquim ;
Petrylak, Daniel Peter ;
Wang Jing ;
Costa, Nuno Matos ;
Laliberte, Robert J. ;
Di Pietro, Alessandra ;
Grivas, Petros ;
Sternberg, Cora N. .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
12345